Ownership and insider activity for Profusa, Inc. Common Stock (PFSA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
Price
| Price | $1.78 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-21 | Knechtel Fred S. | J-Other | 54,323 | |
| 2026-08-21 | Knechtel Fred S. | J-Other | 301,991 | |
| 2026-08-21 | STOVER JACK E | J-Other | 32,018 | |
| 2026-08-21 | STOVER JACK E | J-Other | 301,991 | |
| 2026-08-12 | Knechtel Fred S. | C-Conversion | 301,991 | $1.3M |
| 2026-08-12 | Knechtel Fred S. | C-Conversion | ||
| 2026-08-12 | STOVER JACK E | C-Conversion | 301,991 | $1.3M |
| 2026-08-12 | STOVER JACK E | C-Conversion | ||
| 2026-08-17 | HRT FINANCIAL LP | S-Sale | 18,395 | $109K |
| 2026-08-14 | HRT FINANCIAL LP | S-Sale | 3,163 | $3K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $856000 | $78000 | $142000 | $191000 | $1.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Receivables | $38000 | 0 | $45000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $958000 | $160000 | $333000 | $260000 | $3.8M |
| Property, Plant & Equipment | $10.1M | 0 | $2000 | 0 | $8000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.4M | $1.0M | $1.9M | $3.1M | $3.8M |
| Accounts Payable | $3.3M | $3.4M | $4.0M | $5.0M | $7.3M |
| Short-term Debt | $15.0M | $31.0M | $40.4M | $48.2M | $6.9M |
| Total Current Liabilities | $21.6M | $35.7M | $46.7M | $57.1M | $22.3M |
| Long-term Debt | $1.2M | 0 | 0 | 0 | $7.9M |
| Total Liabilities | $95.0M | $100.8M | $111.9M | $122.3M | $30.4M |
| Retained Earnings | -$85.2M | -$105.4M | -$115.7M | -$125.0M | -$160.8M |
| Total Equity | -$83.7M | -$99.8M | -$110.0M | -$119.2M | -$26.7M |
| Total Debt | $24.0M | $31.0M | $40.4M | $48.2M | $14.8M |
| Net Debt | $23.2M | $31.0M | $40.3M | $48.0M | $13.0M |
| Working Capital | -$20.7M | -$35.5M | -$46.4M | -$56.9M | -$18.5M |
Financial Health
| Debt / Equity | -0.52 |
| Current Ratio | 0.03 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -77.01 |
Profitability
| Return on Equity | 134.38% |
| Return on Invested Capital | 114.53% |
| Return on Assets | -948.95% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · BCDA · BFRI · CHEK · GBS
Explore sector: Healthcare · Medical - Devices
More sections of PFSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks